Synta Pharmaceuticals Corp. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

SNTA 0.361 +0.001 (0.25%)
price chart
Synta Pharmaceuticals Corp. (SNTA) Analyst Review
A number of investment brokers have recently updated their price targets on shares of Synta Pharmaceuticals Corp. (SNTA). According to the latest broker reports outstanding on Friday 27th of May, 0 analysts have a rating of “strong buy”, 0 analysts ...
Synta Pharmaceuticals Corp (NASDAQ:SNTA) Merges Into A Winner
We told our readers and subscribers that Synta Pharmaceuticals Corp (NASDAQ:SNTA) was due for a bounce on February 1. We also said that there was a possibility of a deal happening after Scott Morenstein was appointed to the board of directors.
Top Biotechnology Stock Picking: Synta Pharmaceuticals Corp. (SNTA ...  Zergwatch
Healthcare Sector Stocks Alert: Synta Pharmaceuticals Corp. (SNTA), Eleven ...  News Oracle
Synta Pharmaceuticals' stock plunges 65% premarket after termination of drug ...
Synta Pharmaceuticals Corp. NASDAQ: SNTA. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
Synta Pharmaceuticals Corp (NASDAQ:SNTA) Due For A Bounce
Shares of Synta Pharmaceuticals Corp (NASDAQ:SNTA) have been taken to the woodshed in the past year. Shares really accelerated to the downside after Synta announced that its lead drug, ganetespib, an Hsp90 inhibitor, was being discontinued in its ...
Synta Pharmaceuticals Corp. (SNTA) Drops 5.6% on May 18
Synta Pharmaceuticals Corp. (SNTA) was one of the Russell 2000's biggest losers for Wednesday May 18 as the stock slid 5.6% to $0.36, a loss of $-0.0214 per share.
Revenue Update on Synta Pharmaceuticals Corp.(NASDAQ:SNTA)  Trade Calls
Recently Changed Price Targets On Synta Pharmaceuticals Corp. (SNTA)  Risers & Fallers
Why Synta Pharmaceuticals Corp Shares Burst Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Synta Announces Chen Schor Named President, Chief Executive Officer and Director  Business Wire (press release)
Earnings Estimates Report: Synta Pharmaceuticals Corp. (SNTA)
Synta Pharmaceuticals Corp. (SNTA) is expected to report Q1 earnings estimated on Thursday 05/05/2016. The company operates in the Biotechnology industry.
Synta Pharmaceuticals Corp. (SNTA) Jumps 6.38% on April 22
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Reported Basic Consolidated EPS Of ...  Vanguard Tribune
Here's Why I'm Betting On Synta Pharmaceuticals (SNTA)
The company is approaching the first interim analysis of its Phase 3 GALAXY-2 trial of ganetespib in second-line non-small-cell lung carcinoma, which, if positive, should unlock considerable shareholder value.
Here's Why Synta Pharmaceuticals Corp (SNTA) Stock Shot up Today
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) investors seem quite excited today, as the stock shot up as high as 82.04%, based on a definitive merger agreement signed between the company and Madrigal Pharmaceuticals—a privately-held company.
15.8% Stake of Synta Pharmaceuticals Corp. (SNTA) Maintained by Caxton ...  The Vista Voice
Synta Pharma (SNTA), Madrigal Pharma Enter All-Stock Merger Agreement
Synta Pharmaceuticals Corp (SNTA): Billionaire Bruce Kovner Buys More Shares
Is this merger a good transaction for Synta Pharmaceuticals Corp shareholders? Billionaire Bruce Kovner thinks so. He filed an amended 13D last week disclosing additional purchases of 60K or so SNTA shares as well as his support for the merger.
Synta Pharmaceuticals Corp. (SNTA) Stock Price Will Hit $1: Analysts  CWRU Observer
Hot Biotech Stocks To Watch Right Now: Incyte (INCY), Synta Pharmaceuticals ...  Zergwatch